NCT04730219进行中（未招募）2 期
An Open Label, Single-arm, Phase 2 Study of Perioperative Tislelizumab Combined With Nab-Paclitaxel Before Cystectomy or Complete TURBT for Patients With Muscle-invasive Urothelial Bladder Cancer.
Tianjin Medical University Second Hospital1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2020年7月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Clinical Complete Response (cCR) rate
研究概览
简要总结
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder cancer (MIBC) prior to cystectomy or complete TURBT. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 3 treatment cycles over 9 weeks followed by standard radical cystectomy or complete TURBT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent.
- •Ability to comply with the protocol.
- •Age ≥ 18 years.
- •Suitable and planned for complete transurethral resection of bladder tumor or radical cystectomy
- •Histopathologically confirmed urothelial carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) urothelial cell pattern.
- •Clinical stage T2-T4a N0 M0 disease by CT (or MRI). If the clinical stage is T2-4aN1-3M0, it must be judged by the investigator. If it is judged that radical surgery can still be performed, it can be included in the study.
- •Expected survival time is greater than 12 weeks.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 1 or
- •Agree to provide tissue examination specimens (used to detect PD-L1 expression, tumor mutation burden, etc.)
- •The organ function level must meet the following requirements:
- •Hematological indicators: absolute neutrophil count ≥1.5×10^9/L, platelet count ≥80×10^9/L, hemoglobin ≥6.0 g/dL (can be maintained by symptomatic treatment);
- •Liver function: total bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper limit of normal value, if there is intrahepatic transaminase ≤ 5 times the upper limit of normal value;
- •Renal function: creatinine ≤ 2 times the upper limit of normal, and creatinine clearance ≥ 30 ml/min;
排除标准
- •Receive live attenuated vaccines within 4 weeks before treatment or plan to receive live attenuated vaccines during the study period.
- •Active, known or suspected autoimmune diseases.
- •Known history of primary immunodeficiency.
- •Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •Female patients who are pregnant or breastfeeding.
- •Untreated acute or chronic active hepatitis B or C infection. In the case of patients receiving antiviral therapy, the doctor will judge whether they are eligible for enrollment according to the individual conditions of the patient while monitoring the virus copy number.
- •Have used immunosuppressive drugs in the past 4 weeks before starting treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroids (that is, prednisolone or equivalent physiological doses of no more than 10 mg/day) Other corticosteroids).
- •Those who are known or suspected to be allergic to tislelizumab and nab paclitaxel.
- •Have a clear history of active tuberculosis.
- •Have received PD-1/PD-L1/CTLA-4 antibody or other immunotherapy in the past.
- •Those who are participating in other clinical research.
- •Reproductive men or women who are likely to become pregnant have not taken reliable contraceptive measures.
- •Uncontrolled concurrent diseases include but are not limited to:
- •HIV-infected persons (HIV antibody positive).
- •Serious infections that are active or poorly clinically controlled.
- •There are serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [ie refers to After drug treatment, it is still greater than or equal to CTCAE Grade 2 hypertension]) evidence.
- •Active bleeding or new thrombotic disease.
研究组 & 干预措施
Tislelizumab and Nab Paclitaxel
Experimental
Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
干预措施: Tislelizumab (Drug)
Tislelizumab and Nab Paclitaxel
Experimental
Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
干预措施: Nab paclitaxel (Drug)
结局指标
主要结局
Clinical Complete Response (cCR) rate
时间窗: At the time of complete transurethral resection of bladder tumor or radical cystectomy (within 12 weeks of the first dose of tislelizumab)
defined as the absence of tumor residual confirmed by surgery (RC-PLND or complete TURBT), negative urine cytology and no evidence of lymph nodes or distant metastasis on imaging.
次要结局
- Objective response rate (ORR)(At the time of complete transurethral resection of bladder tumor or radical cystectomy (within 12 weeks of the first dose of tislelizumab))
- Event-free survival (EFS)(up to 3 years)
- Overall Survival (OS)(up to 3 years)
- Disease-specific survival (DSS)(up to 3 years)
- Number of adverse events and severity by grade (CTCAE)(up to 1 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center StudyHigh-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNCT05418309Tianjin Medical University Second Hospital63
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableHigh-RiskNon-Muscle Invasive Bladder Urothelial CarcinomaNCT04730232Tianjin Medical University Second Hospital63
进行中（未招募）
2 期
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRCColorectal NeoplasmsNCT05143099Shanghai Zhongshan Hospital35
招募中
2 期
Tislelizumab Plus Lenvatinib in Stage III-IV RCCAdvanced Kidney CancerNCT05485883Tianjin Medical University Second Hospital20
已完成
2 期
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaHead and Neck CancerHead and Neck CancerNCT05909904BeiGene160